In the past number of years, the united kingdom has witnessed a revolution in professional medical weight‑decline therapies — with the introduction of semaglutide (Wegovy®) to the developing attractiveness of tirzepatide (Mounjaro®). Now, A further identify is drawing attention in the two clinica